| Ytd | 35.56% | |
| 1y | 212.35% |
| Open | 38.71 | Prev Close | 38.91 | Low | 37.39 | High | 39.10 | Mkt Cap | 1.76B |
| Vol | 132.03K | Avg Vol | 446.06K | EPS | -0.53 | P/E | N/A | Forward P/E | -20.05 |
| Beta | 2.29 | Short Ratio | 7.05 | Inst. Own | 98.69% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-09 | 50-d Avg | 37.34 | 200-d Avg | 29.28 | 1yr Est | 54.22 |
SEPN News
Septerna, Inc. has surged >315% since May 2025, driven by its GPCR-focused drug discovery and a high
SOUTH SAN FRANCISCO, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clin
JP Morgan analyst Tessa Romero maintains Septerna (NASDAQ:SEPN) with a Overweight and raises the
Jones Trading analyst Catherine Novack maintains Septerna (NASDAQ:SEPN) with a Buy and raises the
Wells Fargo analyst Derek Archila maintains Septerna (NASDAQ:SEPN) with a Overweight and raises t
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Septerna (NASDAQ:SEPN) with a Buy an
Guggenheim analyst Seamus Fernandez maintains Septerna (NASDAQ:SEPN) with a Buy and raises the pr
Septerna, Inc. (SEPN) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus E
Septerna (NASDAQ:SEPN) reported quarterly losses of $(0.29) per share which beat the analyst consens
US stocks were mixed, Nasdaq fell 1%. DigitalOcean shares rose after strong revenue growth and earni
Samira Shaikhly sold 11,798 shares of Common Stock on May 26, 2026, for a transaction value of ~$355
Guggenheim analyst Seamus Fernandez maintains Septerna (NASDAQ:SEPN) with a Buy and lowers the pr
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Septerna (NASDAQ:SEPN) with a Buy a
Truist Securities analyst Srikripa Devarakonda maintains Septerna (NASDAQ:SEPN) with a Buy and ra
15,000 shares were exercised and sold for a total of ~$533,000 on June 22, 2026, at a weighted avera
Raymond James analyst Martin Auster maintains Septerna (NASDAQ:SEPN) with a Strong Buy and raises
Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G prote
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotec
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Septerna (NASDAQ:SEPN) with a Buy a
Septerna, Inc. (SEPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Septerna, Inc. (SEPN) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus E
Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development
SOUTH SAN FRANCISCO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clini
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Septerna (NASDAQ:SEPN) with a Buy a
Trial Designed to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SEP-47
Trial Designed to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SEP-47
JP Morgan analyst Tessa Romero maintains Septerna (NASDAQ:SEPN) with a Overweight and raises the
Truist Securities analyst Srikripa Devarakonda maintains Septerna (NASDAQ:SEPN) with a Buy and ra
Common StockPreferred StockDebt SecuritiesWarrantsUnitsWe may from time to time issue, in one or mor
Septerna, Inc. (SEPN) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus E
Septerna (NASDAQ:SEPN) reported quarterly losses of $(0.24) per share which missed the analyst conse
Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development
Wells Fargo analyst Derek Archila maintains Septerna (NASDAQ:SEPN) with a Overweight and raises t
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Septerna (NASDAQ:SEPN) with a Buy an
SEP-631 Demonstrated Robust, Dose-Dependent Inhibition of Icatibant-Induced Skin Wheal Formation, wi
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clin
Septerna, Inc. (NASDAQ: SEPN - Get Free Report)'s stock price traded down 5.9% during trading on Fri
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clin
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clin
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Septerna (NASDAQ:SEPN) with a Buy an
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clin
Jones Trading analyst Catherine Novack initiates coverage on Septerna (NASDAQ:SEPN) with a Buy ra
Raymond James analyst Martin Auster initiates coverage on Septerna (NASDAQ:SEPN) with a Strong Bu
SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clin